tirzepatide and menopause symptoms New research from a Mayo Clinic–led study suggests that postmenopausal women using hormone therapy may experience greater weight loss when treated with tirzepatide, a GLP-1–based medication for overweight obesity. In HRT and Tirzepatide: The Key

Stapleton M, Howard-Thompson A, George C, Hoover RM, Self TH

Physical Activity Regular physical activity helps burn calories and improve overall health, complementing the medications effects on appetite and weight management

Berg Show LIVE - June 19, 2026 When it comes to your health, most people try to fix everything at once

Allowing the medication to reach room temperature before injecting also helps

Both medications contain glucagon-like peptide-1 (GLP-1) receptor agonists

These signals included dizziness (ROR, 1.30, 95% CI 1.271.33), tremor (1.37, 1.321.42), dysgeusia (1.72, 1.641.81), lethargy (1.24, 1.151.33), taste disorder (2.55, 2.332.80), presyncope (1.39, 1.251.54), parosmia (2.39, 2.072.75), allodynia (25.55, 21.7130.08), hypoglycemic unconsciousness (8.11, 6.949.46), brain fog (1.78, 1.512.10), hyperesthesia (1.40, 1.181.66), diabetic neuropathy (1.95, 1.612.36), hypoglycemic seizure (3.29, 2.324.66), ophthalmic migraine (3.14, 1.885.27), Wernickes encephalopathy (2.37, 1.394.04), diabetic hyperglycemic coma (3.07, 1.685.62), hyperglycemic unconsciousness (7.94, 4.2714.77), vagus nerve disorder (3.75, 1.927.32), and hyperglycemic seizure (5.85, 1.8118.90) (Fig